Paul F. Lizzul

Paul F. Lizzul, listed as senior executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Anaptysbio, Inc and Sienna Biopharmaceuticals, Inc. We count 25 filings; the first trade dates from 1 August 2017 and the latest from 7 January 2026.

Both buying and selling appear: 1 purchase worth €127k, against 5 sales worth €401k. The net balance comes to €274k on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 6 share grants and 12 option exercises. So far in 2026, the count stands at no purchases and 1 sale.

Most recently, on 9 January 2026, the filings show an option exercise in Anaptysbio, Inc. The clock since the last published purchase (1 August 2017) now reads 3,368 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.